A prospective, multicenter, randomized, controlled study to evaluate the clinical outcome of Zhenyuan capsule in the treatment of heart failure after myocardial infarction

Zhongshan Hospital affiliated to Fudan University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) 18 years old = age = 85 years old.
•(2) The admission diagnosis is consistent with acute myocardial infarction within 28 days (within 28 days of onset).
•(3) Heart failure occurs after this myocardial infarction, and the diagnostic criteria for heart failure include:
•a) Symptoms and/or signs of heart failure, and Killip class II-IV or NYHA class II-IV;
•b) NT-proBNP = 300 pg/ml (= 600 pg/ml in patients with atrial fibrillation), or BNP = 100 pg/ml (= 200 pg/ml in patients with atrial fibrillation) detected at any time after admission.
•(4) The patients are willing to follow the research protocol and sign the informed consent.

•(1) Pregnant women or patients planning to become pregnant within 1 year.
•(2) Patients receiving intra-aortic balloon counterpulsation and endotracheal intubation.
•(3) History of dilated cardiomyopathy, perinatal cardiomyopathy, chemotherapy-induced cardiomyopathy, hereditary hypertrophic cardiomyopathy, invasive cardiomyopathy, and viral myocarditis.
•(4) Have a history of moderate or above valvular disease.
•(5) Severe abnormal liver function (ALT or AST exceeding 3 times the upper limit of the normal range (ULN), or total bilirubin>1.5mg/dl), abnormal renal function (eGFR<30ml/min/1.73) due to non-cardiac causes m2).
•(6) Patients with malignant tumors.
•(7) History of drug or alcohol abuse within the past 12 months.
•(8) Participate in other clinical studies within 1 month before enrollment.

发起方

Zhongshan Hospital affiliated to Fudan University